SPOTLIGHT: Back end deal for CrystalGenomics


CrystalGenomics/CG Pharmaceuticals announced a strategic alliance agreement with ProQuest Investments to identify and develop orally available drugs that modulate the HIF Prolyl Hydroxylase enzyme system. Under the agreement, CrystalGenomics will receive up to $6 million in upfront and initial research funding from Palkion, in addition to development and sales milestone payments of potentially more than $200 million. Release

Suggested Articles

AstraZeneca is picking up a delayed preclinical fibrosis candidate from RedX in a deal that gives the U.K. biotech a much needed cash boost.

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.